Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPD - 12/08/11
, Bartolome R. Celli, MD d, David M. Mannino, MD e, Thomas Petty, MD f, Stephen I. Rennard, MD g, Frank C. Sciurba, MD h, James K. Stoller, MD, MS i, Byron M. Thomashow, MD b, Gerard M. Turino, MD j
Requests for reprints should be addressed to R. Graham Barr, MD, DrPH, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032Abstract |
Objective |
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States but is often undertreated. COPD often overlaps with other conditions such as hypertension and osteoporosis, which are less morbid but may be treated more aggressively. We evaluated the prevalence of these comorbid conditions and compared testing, patient knowledge, and management in a national sample of patients with COPD.
Methods |
A survey was administered by telephone in 2006 to 1003 patients with COPD to evaluate the prevalence of comorbid conditions, diagnostic testing, knowledge, and management using standardized instruments. The completion rate was 87%.
Results |
Among 1003 patients with COPD, 61% reported moderate or severe dyspnea and 41% reported a prior hospitalization for COPD. The most prevalent comorbid diagnoses were hypertension (55%), hypercholesterolemia (52%), depression (37%), cataracts (31%), and osteoporosis (28%). Only 10% of respondents knew their forced expiratory volume in 1 second (95% confidence interval [CI], 8-12) compared with 79% who knew their blood pressure (95% CI, 76-83). Seventy-two percent (95% CI, 69-75) reported taking any medication for COPD, usually a short-acting bronchodilator, whereas 87% (95% CI, 84-90) of patients with COPD and hypertension were taking an antihypertensive medication and 72% (95% CI, 68-75) of patients with COPD and hypercholesterolemia were taking a statin.
Conclusion |
Although most patients with COPD in this national sample were symptomatic and many had been hospitalized for COPD, COPD self-knowledge was low and COPD was undertreated compared with generally asymptomatic, less morbid conditions such as hypertension.
Le texte complet de cet article est disponible en PDF.Keywords : Asthma, Chronic bronchitis, Chronic obstructive pulmonary disease, Comorbidities, Emphysema
Plan
| Funding: The COPD Foundation and National Institutes of Health HL077612 and HL075476. |
|
| Conflict of Interest: R. Graham Barr, MD, DrPH: none. Bartolome R. Celli, MD: research grants from Glaxo Smith Kline (GSK), Boehringer Ingelheim (BI), Forrest Medical, Astra Zeneca; advisory board payments from GSK, BI, Almirall, Astra Zeneca; speakers' fees from GSK, BI, Astra Zeneca, Almirall. David Mannino, MD: research funding from GSK, Pfizer, and Novartis; consultant or speakers' fees from GSK, Pfizer, BI, Astra-Zeneca, Dey, and Sepracor. Thomas Petty, MD: none. Stephen I. Rennard, MD: research grants from Almirall, Lorillard, Centocor, Novartis, GSK, Philip Morris, Institute for Science and Health, Roche; consultancy and advisory board payments from Abbott, Johnson & Johnson, Almirall, Novartis, Altana, Roche, Anthera, Quintiles, GSK, Targegen; speakers' fees from Adams, Novartis, AstraZeneca, Pfizer. Frank C. Sciurba, MD: consultancy for Astra Zeneca, BI, Dey, GSK, Novartis, Pfizer, PneumRX, Respironics, Schering and Sepracor. James K. Stoller, MD, MS: consultancy for Talecris Biotherapeutics, BI; speaker for Grifols, Baxter, CSL-Behring, Pfizer, Talecris. Byron M. Thomashow, MD: speakers' fees and consultancy for BI, Pfizer and GSK. Gerard M. Turino, MD: research grant from BI; consultancy for Talecris Corporation. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 122 - N° 4
P. 348-355 - avril 2009 Retour au numéro
Article précédent
- Post-Pacemaker Pulsations
- Norman C. Wang, Jeffrey L. Williams, Sandeep K. Jain, Alaa Shalaby
- Long-Acting Calcium Antagonists in Patients with Coronary Artery Disease: A Meta-Analysis
- Sripal Bangalore, Sanobar Parkar, Franz H. Messerli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?